文献速递心律失常血脂与心血管预防

阿哌沙班在终末期肾病合并房颤患者中的结局

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
PubMed 文献 · Circulation · 2018-01-01

本研究基于美国肾脏数据系统对透析依赖的终末期肾病合并房颤患者进行回顾性队列研究,比较阿哌沙班与华法林的安全性和有效性。匹配队列中,阿哌沙班与华法林在卒中/系统性栓塞风险上无差异,但大出血风险显著更低;标准剂量5mg每日两次的阿哌沙班相比减量或华法林与更低的卒中/系统性栓塞和死亡风险相关。

要点

  • 透析房颤患者中,阿哌沙班大出血风险低于华法林。
  • 标准剂量5mg每日两次可能降低血栓栓塞和死亡风险。
  • 阿哌沙班与华法林在卒中/系统性栓塞风险上无显著差异。

核心结论

  • 透析依赖的终末期肾病合并房颤患者中,阿哌沙班使用可能与华法林相比大出血风险更低。
  • 标准5mg每日两次剂量还与血栓栓塞和死亡风险降低相关。

研究设计与样本

  • 回顾性队列研究,使用美国肾脏数据系统2010年10月至2015年12月的医疗保险受益人数据。
  • 阿哌沙班与华法林按预后评分1:3匹配,采用Kaplan-Meier分析和Cox回归评估结局。

主要发现

  • 2012年底上市后阿哌沙班处方逐年增加,2015年占新抗凝处方的26.6%。
  • 匹配队列中,阿哌沙班与华法林相比卒中/系统性栓塞风险无差异(HR 0.88,95%CI 0.69-1.12,P=0.29)。
  • 阿哌沙班与大出血风险显著降低相关(HR 0.72,95%CI 0.59-0.87,P<0.001)。
  • 敏感性分析中,标准剂量阿哌沙班(5mg每日两次,n=1034)相比减量阿哌沙班(2.5mg每日两次,n=1317)卒中/系统性栓塞风险更低(HR 0.61,95%CI 0.37-0.98,P=0.04),死亡风险更低(HR 0.64,95%CI 0.45-0.92,P=0.01)。
  • 标准剂量阿哌沙班相比华法林卒中/系统性栓塞风险更低(HR 0.64,95%CI 0.42-0.97,P=0.04),死亡风险更低(HR 0.63,95%CI 0.46-0.85,P=0.003)。

临床怎么用

  • 对于透析依赖的终末期肾病合并房颤患者,阿哌沙班可作为华法林的替代选择,尤其关注大出血风险降低。
  • 标准剂量5mg每日两次可能带来额外获益,但需结合患者个体情况评估。

局限性

  • 回顾性观察性研究,可能存在残余混杂。
  • 达比加群和利伐沙班使用者数量少,未评估其结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised concerns regarding the safety of dabigatran and rivaroxaban, but apixaban has not been evaluated despite current labeling supporting its use in this population. The goal of this study was to determine patterns of apixaban use and its associated outcomes in dialysis-dependent patients with ESKD and AF. METHODS: We performed a retrospective cohort study of Medicare beneficiaries included in the United States Renal Data System (October 2010 to December 2015). Eligible patients were those with ESKD and AF undergoing dialysis who initiated treatment with an oral anticoagulant. Because of the small number of dabigatran and rivaroxaban users, outcomes were only assessed in patients treated with apixaban or warfarin. Apixaban and warfarin patients were matched (1:3) based on prognostic score. Differences between groups in survival free of stroke or systemic embolism, major bleeding, gastrointestinal bleeding, intracranial bleeding, and death were assessed using Kaplan-Meier analyses. Hazard ratios (HRs) and 95% CIs were derived from Cox regression analyses. RESULTS: The study population consisted of 25 523 patients (45.7% women; 68.2±11.9 years of age), including 2351 patients on apixaban and 23 172 patients on warfarin. An annual increase in apixaban prescriptions was observed after its marketing approval at the end of 2012, such that 26.6% of new anticoagulant prescriptions in 2015 were for apixaban. In matched cohorts, there was no difference in the risks of stroke/systemic embolism between apixaban and warfarin (HR, 0.88; 95% CI, 0.69-1.12; P=0.29), but apixaban was associated with a significantly lower risk of major bleeding (HR, 0.72; 95% CI, 0.59-0.87; P<0.001). In sensitivity analyses, standard-dose apixaban (5 mg twice a day; n=1034) was associated with significantly lower risks of stroke/systemic embolism and death as compared with either reduced-dose apixaban (2.5 mg twice a day; n=1317; HR, 0.61; 95% CI, 0.37-0.98; P=0.04 for stroke/systemic embolism; HR, 0.64; 95% CI, 0.45-0.92; P=0.01 for death) or warfarin (HR, 0.64; 95% CI, 0.42-0.97; P=0.04 for stroke/systemic embolism; HR, 0.63; 95% CI, 0.46-0.85; P=0.003 for death). CONCLUSIONS: Among patients with ESKD and AF on dialysis, apixaban use may be associated with a lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018. PMID: 29954737. doi:10.1161/CIRCULATIONAHA.118.035418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。